9 unknown, 3 not yet recruiting, 2 terminated, 1 active not recruiting. 17 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Unknown 9, Not yet recruiting 3, Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Neoadjuvant Chemotherapy: new trials by email Literature Review of Neoadjuvant Chemotherapy trials Research Report on Neoadjuvant Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients Envafolimab and neoadjuvant chemotherapy - Osteosarcoma, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 23 | 2025-08-25 | 2025-08-27 |
| Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer SOX+Sintilimab, FLOT+Sintilimab - Neoadjuvant Chemotherapy, Sintilimab | Phase 2 | Not yet recruiting | Xijing Hospital | 200 | 2024-12-01 | 2024-10-10 |
| Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab irinotecan liposome + oxaliplatin + 5-FU / LV, Adebellizumab - Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer | Phase 2 | Not yet recruiting | Zhejiang University | 180 | 2024-01-20 | 2023-12-15 |
| Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy - Neoadjuvant Chemotherapy, PD-1 Antibody | Phase 2 | Unknown | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 36 | 2023-08-01 | 2024-07-25 |
| Toripalimab-based Neoadjuvant Therapy in LA-HNSCC AP combined with or without Toripalimab - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 122 | 2022-09-02 | 2026-07-17 |
| FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer Oxaliplatin, Irinotecan, Folinic Acid - High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy | Phase 2 | Unknown | West China Hospital | 69 | 2021-08-02 | 2021-08-24 |
| PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer BGB-A317, albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 - Ovarian Cancer, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2021-04-01 | 2021-03-25 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Pembrolizumab Injection [Keytruda] - Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2021-04-01 | 2021-03-24 |
| Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial) HIPEC, intravenous chemotherapy - Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2020-12-01 | 2022-02-18 |
| Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer Epirubicin, Cyclophosphamid, Docetaxel - HER2-negative Breast Cancer, Neoadjuvant Chemotherapy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 260 | 2020-09-20 | 2021-08-12 |
| NAC Followed by RH for the Treatment of LACC Two cycles of neoadjuvant chemotherapy, First imaging evaluation, Second imaging evaluation - Neoadjuvant Chemotherapy, Locally Advanced Cervical Cancer | Phase 2 | Unknown | Lei Li | 60 | 2019-06-19 | 2019-06-20 |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma dose dense MVAC with pegylated GCSF - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | Pusan National University Yangsan Hospital | 24 | 2019-05-01 | 2026-09-18 |
| ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Doxorubicin liposome, Cyclophosphamide, Trastuzumab - Breast Cancer, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Sun Yat-sen University | 156 | 2019-01-10 | 2023-10-16 |
| Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Epirubicin, Fluorouracil, Docetaxel - Breast Cancer, Pathological Complete Response | Phase 2 / Phase 3 | Unknown | Zhiyong Yu | 200 | 2017-11-27 | 2017-11-21 |
| Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer S1,, Paclitaxel-albumin - Pancreatic Cancer, Neoadjuvant Chemotherapy | Phase 2 | Terminated | Zhejiang Provincial People's Hospital | 40 | 2017-11-20 | 2021-01-08 |
| DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer Fasting mimicking diet - Fasting Mimicking Diet, Breast Cancer | Phase 2 / Phase 3 | Completed | Leiden University Medical Center | 131 | 2014-02-01 | 2019-10-24 |
| Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer Paclitaxel and carboplatin, Paclitaxel, Epirubicin and Paclitaxel - Breast Cancer, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 200 | 2014-01-01 | 2014-11-25 |
Breast Neoplasms (4) · Carcinoma, Transitional Cell (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (8) · Breast Diseases (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Neoplasms by Histologic Type (3) · Carcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms, Glandular and Epithelial (2)
Epirubicin (4) · Fluorouracil (4) · Cyclophosphamide (3) · Docetaxel (3) · Paclitaxel (3) · Doxorubicin (2) · Oxaliplatin (2) · 1-dodecylpyridoxal (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Irinotecan (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Chinese Academy of Medical Sciences (1) · Lei Li (1) · Leiden University Medical Center (1) · Pusan National University Yangsan Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Jiao Tong University Affiliated Sixth People's Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · West China Hospital (1) · Xijing Hospital (1) · Zhejiang Provincial People's Hospital (1) · Zhejiang University (1) · Zhiyong Yu (1)
China (12) · Netherlands (1) · South Korea (1)
Binghe Xu, MD (1) · Hanno Pijl, MD PhD (1) · Jianwei Zhou, MD (1) · Jie Fu, Dr (1) · Jing Li, Doctor (1) · Judith R Kroep, MD, PhD (1) · Kwonoh Park, MD, PhD (1) · Lei Li, M.D. (1) · Weibing Leng, Ph.D (1) · Wen Xia, MD (1) · Xiaoshan Cao, MD (1) · Yiding Chen (1) · Zhiyong Yu, PhD (1)
PMID 11352955, PMID 11600601, PMID 12586807, PMID 12771730, PMID 12944571, PMID 15939524, PMID 16034041, PMID 21502557, PMID 24373477, PMID 24472710, PMID 24669010, PMID 24821881, PMID 24821883, PMID 25257030, PMID 26205531, PMID 26421586, PMID 27053504, PMID 28625005, PMID 29329894, PMID 32576828, PMID 33179154, PMID 36720570, PMID 39909529